Eli Lilly (NYSE:LLY) reported Phase 3 data showing its triple-agonist retatrutide outperformed Novo Nordisk's Ozempic in type 2 diabetes. The long term head to head trial indicated stronger glycemic control and weight loss effects for retatrutide than Ozempic in the study population. Lilly resolved a legal dispute with Novo Nordisk over product marketing and outlined a leadership reshuffle that consolidates global business units. Retatrutide's Phase 3 edge over Ozempic and Lilly's leadership overhaul are part of a broader shift our research has tracked. Our analysis turns up 1 warning sign for Eli Lilly as well.
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.